Citigroup Inc. Sells 111,996 Shares of Bionano Genomics, Inc. (NASDAQ:BNGO)

Citigroup Inc. reduced its stake in shares of Bionano Genomics, Inc. (NASDAQ:BNGOFree Report) by 90.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,526 shares of the company’s stock after selling 111,996 shares during the quarter. Citigroup Inc.’s holdings in Bionano Genomics were worth $35,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BNGO. BlackRock Inc. increased its position in shares of Bionano Genomics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 21,617,405 shares of the company’s stock valued at $39,561,000 after purchasing an additional 595,830 shares during the last quarter. Vanguard Group Inc. increased its position in Bionano Genomics by 7.1% during the first quarter. Vanguard Group Inc. now owns 15,876,289 shares of the company’s stock valued at $40,961,000 after acquiring an additional 1,050,655 shares during the last quarter. State Street Corp raised its stake in shares of Bionano Genomics by 2.6% in the first quarter. State Street Corp now owns 10,691,423 shares of the company’s stock valued at $11,866,000 after acquiring an additional 266,511 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Bionano Genomics by 4.4% in the 1st quarter. Geode Capital Management LLC now owns 5,794,277 shares of the company’s stock worth $6,432,000 after acquiring an additional 243,361 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Bionano Genomics by 3,261.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,657,513 shares of the company’s stock worth $5,047,000 after purchasing an additional 3,548,719 shares during the period. 11.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Scotiabank reduced their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research report on Thursday, March 7th.

Check Out Our Latest Stock Analysis on Bionano Genomics

Bionano Genomics Stock Performance

BNGO stock opened at $1.00 on Wednesday. Bionano Genomics, Inc. has a twelve month low of $0.96 and a twelve month high of $11.80. The firm has a market cap of $54.55 million, a price-to-earnings ratio of -0.15 and a beta of 2.33. The business’s fifty day simple moving average is $1.15 and its two-hundred day simple moving average is $1.59. The company has a quick ratio of 1.17, a current ratio of 1.40 and a debt-to-equity ratio of 0.04.

Bionano Genomics (NASDAQ:BNGOGet Free Report) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.96) EPS for the quarter. Bionano Genomics had a negative return on equity of 103.68% and a negative net margin of 643.74%. The company had revenue of $10.72 million during the quarter. Analysts predict that Bionano Genomics, Inc. will post -2.35 earnings per share for the current year.

Bionano Genomics Company Profile

(Free Report)

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.

Further Reading

Want to see what other hedge funds are holding BNGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bionano Genomics, Inc. (NASDAQ:BNGOFree Report).

Institutional Ownership by Quarter for Bionano Genomics (NASDAQ:BNGO)

Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.